Timothy Affolter

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Helen Y. Zou, Luc Friboulet, David P. Kodack et al. · Cancer Cell · 2015 · 463 citations · Full text

Medicine, Oncology, Pharmacology +14

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Helen Y. Zou, Qiuhua Li, Lars D. Engstrom et al. · Proceedings of the National Academy of Sciences · 2015 · 269 citations · Full text

Medicine, Oncology, Pharmacology +15

Anti–IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function

Li‐Fen Lee, Kathryn Logronio, Guang Huan Tu et al. · Proceedings of the National Academy of Sciences · 2012 · 135 citations · Full text

Life Sciences, Endocrinology, Immunology +17

[18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells

Cathy C. Zhang, Zhengming Yan, Wenlin Li et al. · Clinical Cancer Research · 2011 · 76 citations

Medicine, Nuclear Medicine, Oncology +17

Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice

Timothy Affolter, Heather P. Llewellyn, Derek W. Bartlett et al. · PLoS ONE · 2019 · 54 citations · Full text

Medicine, Oncology, Pharmacology +17